Alpha 2.0
Login Register
» Authors » Laura B Amsden

Laura B Amsden

Explore the profile of Laura B Amsden including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 30
Citations 285
Followers 0
Related Specialties
General Medicine
Pediatrics
Ophthalmology
Top 10 Co-Authors
Liyan Liu
Lisa J Herrinton
Jacek Skarbinski
Jane L Holl
Joshua R Nugent
Neal H Shorstein
Mariah S Wood
Douglas A Corley
Crystal A Hsiao
James Carolan
Published In
PLoS One
medRxiv
J Cataract Refract Surg
Pediatrics
Pharmacoepidemiol Drug Saf
Affiliations
Soon will be listed here.
Recent Articles
1.
SARS-CoV-2 Omicron subvariant genomic variation associations with immune evasion in Northern California: A retrospective cohort study
Nugent J, Wood M, Liu L, Bullick T, Schapiro J, Arunleung P, et al.
PLoS One . 2025 Feb; 20(2):e0319218. PMID: 39992939
Background: The possibility of association between SARS-CoV-2 genomic variation and immune evasion is not known among persons with Omicron variant SARS-CoV-2 infection. Methods: In a retrospective cohort, using Poisson regression...
2.
Impact of COVID-19 on myalgic encephalomyelitis/chronic fatigue syndrome-like illness prevalence: A cross-sectional survey
Wood M, Halmer N, Bertolli J, Amsden L, Nugent J, Lin J, et al.
PLoS One . 2024 Sep; 19(9):e0309810. PMID: 39292671
Background: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) can be triggered by infectious agents including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the impact of the coronavirus disease 2019 (COVID-19) pandemic...
3.
SARS-CoV-2 Omicron subvariant genomic variation associations with immune evasion in Northern California: A retrospective cohort study
Nugent J, Wood M, Liu L, Bullick T, Schapiro J, Arunleung P, et al.
medRxiv . 2024 Sep; PMID: 39228703
Background: The possibility of association between SARS-CoV-2 genomic variation and immune evasion is not known among persons with Omicron variant SARS-CoV-2 infection. Methods: In a retrospective cohort, using Poisson regression...
4.
Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system
Chervo T, Elkin E, Nugent J, Valice E, Amsden L, Ergas I, et al.
PLoS One . 2024 Jun; 19(6):e0303303. PMID: 38900738
Background: Understanding the relative contributions of SARS-CoV-2 infection-induced and vaccine-induced seroprevalence is key to measuring overall population-level seroprevalence and help guide policy decisions. Methods: Using a series of six population-based...
5.
Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system
Chervo T, Elkin E, Nugent J, Valice E, Amsden L, Ergas I, et al.
medRxiv . 2024 Feb; PMID: 38352327
Background: Understanding the relative contributions of SARS-CoV-2 infection-induced and vaccine- induced seroprevalence is key to measuring overall population-level seroprevalence and help guide policy decisions. Methods: Using a series of six...
6.
Real-World Evidence to Supplement Randomized Clinical Trials: Tocilizumab for Severe COVID-19 Pneumonia vs. a Cohort Receiving Standard of Care
Skarbinski J, Fischer H, Hong V, Liu L, Yau V, Incerti D, et al.
Clin Pharmacol Ther . 2023 Aug; 114(5):1073-1081. PMID: 37571812
Randomized controlled trials (RCTs) remain the gold standard for evaluating treatment efficacy, but real-world evidence can supplement RCT results. Tocilizumab was not found to reduce 28-day mortality in a phase...
7.
Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Genomic Variation Associated With Breakthrough Infection in Northern California: A Retrospective Cohort Study
Skarbinski J, Nugent J, Wood M, Liu L, Bullick T, Schapiro J, et al.
J Infect Dis . 2023 May; 228(7):878-888. PMID: 37195913
Background: The association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomic variation and breakthrough infection is not well defined among persons with Delta variant SARS-CoV-2 infection. Methods: In a...
8.
Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19
Skarbinski J, Liu L, Hong V, Amsden L, Fireman B, Yau V, et al.
BMJ Open . 2022 Oct; 12(10):e060358. PMID: 36316080
Objectives: Assess the association between tocilizumab administration and clinical outcomes among mechanically ventilated patients with COVID-19 pneumonia. Design: Retrospective cohort study. Setting: Large integrated health system with 9 million members...
9.
Development and validation of a prediction algorithm to identify birth in countries with high tuberculosis incidence in two large California health systems
Fischer H, Qian L, Skarbinski J, Bruxvoort K, Wei R, Li K, et al.
PLoS One . 2022 Aug; 17(8):e0273363. PMID: 36006985
Objective: Though targeted testing for latent tuberculosis infection ("LTBI") for persons born in countries with high tuberculosis incidence ("HTBIC") is recommended in health care settings, this information is not routinely...
10.
Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study
Skarbinski J, Wood M, Chervo T, Schapiro J, Elkin E, Valice E, et al.
Lancet Reg Health Am . 2022 Jun; 12:100297. PMID: 35756977
Background: The incidence of and risk factors for severe clinical outcomes with the Omicron (B.1.1.529) SARS-CoV-2 variant have not been well-defined. Methods: We conducted a retrospective cohort study to assess...